Mitsubishi Chemical Corporation

Mitsubishi Kasei Corporation

Akira Maruyama

Akihiro Tobe

Satoshi Yamazaki

Shigeru Ogawa

Hiroaki Ueno

Takayuki Oe

Katsuhiko Masuda

The invention relates to type A crystal of 5-&lsqb;&lcub;6-(2-fluorobenzyl)oxy-2-naphthyl&rcub;methyl&rsqb;-2,4-thiazolidinedione characterized to have characteristic absorption peaks (2&thgr;) at 11.5&deg;&plusmn;0.3&deg;, 14.5&deg;&plusmn;0.2&deg;, 16.2&deg;&plusmn;0.3&deg;, 17.0&deg;&plusmn;0.3&deg;, 17.7&deg;&plusmn;0.2&deg;, 18.6&deg;&plusmn;0.3&deg;, 19.1&deg;&plusmn;0.2&deg;, 21.3&deg;&plusmn;0.4&deg;, 22.4&deg;&plusmn;0.5&deg;, 25.7&deg;&plusmn;0.5&deg; and 28.3&deg;&plusmn;0.5&deg; in a powder X-ray diffraction pattern, and also to a method for preparation thereof, and a pharmaceutical composition comprising the same. The crystal is excellent in stability, and has advantages in handling, storage, and pharmaceutical preparation. The invention also relates to type B, C and D crystals of said compound.

Crystals of 5-&lsqb;&lcub;6-(2-fluorobenzyl)oxy-2-naphthyl&rcub;methyl&rsqb;-2,4-thiazolidinedione

A novel cinnoline derivative having an antagonistic activity against serotonin 5-HT.sub.3 receptor, its pharmaceutically acceptable salts, its N-oxide derivatives or solvates thereof, and pharmaceutical formulations containing the same for the prevention and/or treatment of various disorders such as nausea and/or emesis caused by anticancer drugs or X-ray treatment, central nervous disorders such as anxiety and/or neuropathy, gastroenteric diseases such as indigestion, chronic gastritis, digestive ulcer, irritable bowel syndromes and the like, hemicrania, cluster headache, trigeminal neuralgia, arrhythmia and the like.

Cinnoline-3-carboxylic acid derivatives

The thieno[3.2-b]pyridine derivative of the present invention promote the gastric emptying in male ddy mice and the gastric contraction in dogs sutured with a strain-gauge transducer. It is believed that the derivatives have the action to enhance gastric motor action and gastric emptying. Therefore, the compound of the present invention are effective for the prevention and therapeutical treatment of the symptoms caused by gastric hypanakinesis, such as heartburn, abdominal distension feeling, anorexia, unpleasant feeling on upper abdomen, abdominalgia, nausea, vomiting, etc. caused by the underlying diseases such as acute and chronic gastritis, stomach and duodenum ulcer, gastroneurosis, gastroptosis, etc. The present invention also encompasses a pharmaceutical composition containing as the effective ingredient a compound of the present invention, and a method for producing the same.

Thieno[3,2-b]pyridine derivatives

Growing community of inventors

Kashima, Japan

Akira Maruyama